Cargando…

Arzneimittelinduzierte Lungenerkrankungen

It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic...

Descripción completa

Detalles Bibliográficos
Autor principal: Ukena, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101552/
https://www.ncbi.nlm.nih.gov/pubmed/32288714
http://dx.doi.org/10.1007/s10405-007-0149-9
_version_ 1783511649699758080
author Ukena, D.
author_facet Ukena, D.
author_sort Ukena, D.
collection PubMed
description It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic work-up includes comprehensive pulmonary function testing with determination of diffusing capacity, high-resolution computed tomography, and bronchoscopy with bronchoalveolar lavage. There is no specific pathological alteration for a defined drug. In case of doubt the potentially pneumotoxic drug should be discontinued. An attempt should be made to treat severely compromised lung function with systemic corticosteroids.
format Online
Article
Text
id pubmed-7101552
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-71015522020-03-31 Arzneimittelinduzierte Lungenerkrankungen Ukena, D. Pneumologe (Berl) CME Weiterbildung • Zertifizierte Fortbildung It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic work-up includes comprehensive pulmonary function testing with determination of diffusing capacity, high-resolution computed tomography, and bronchoscopy with bronchoalveolar lavage. There is no specific pathological alteration for a defined drug. In case of doubt the potentially pneumotoxic drug should be discontinued. An attempt should be made to treat severely compromised lung function with systemic corticosteroids. Springer-Verlag 2007-04-26 2007 /pmc/articles/PMC7101552/ /pubmed/32288714 http://dx.doi.org/10.1007/s10405-007-0149-9 Text en © Springer Medizin Verlag 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle CME Weiterbildung • Zertifizierte Fortbildung
Ukena, D.
Arzneimittelinduzierte Lungenerkrankungen
title Arzneimittelinduzierte Lungenerkrankungen
title_full Arzneimittelinduzierte Lungenerkrankungen
title_fullStr Arzneimittelinduzierte Lungenerkrankungen
title_full_unstemmed Arzneimittelinduzierte Lungenerkrankungen
title_short Arzneimittelinduzierte Lungenerkrankungen
title_sort arzneimittelinduzierte lungenerkrankungen
topic CME Weiterbildung • Zertifizierte Fortbildung
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101552/
https://www.ncbi.nlm.nih.gov/pubmed/32288714
http://dx.doi.org/10.1007/s10405-007-0149-9
work_keys_str_mv AT ukenad arzneimittelinduziertelungenerkrankungen